2023 World Conference on Lung Cancer (Posters)-EP06.03. Clinical Study to Molecularly Profile Filipino Lung Adenocarcinoma

EP06.03. Clinical Study to Molecularly Profile Filipino Lung Adenocarcinoma - PDF(Abstract)

Pdf Summary

This clinical study aimed to determine the molecular profile of Filipino patients with lung adenocarcinoma, the leading cause of cancer death worldwide. Twenty-six patients were recruited and their tumor tissue and blood samples were collected and processed for molecular profiling. The study found that 50% of the cases exhibited EGFR mutations, and 18.2% were positive for the ALK mutation. The majority of patients were males, and 54% were in stage IV of lung cancer. The study also found that the circulating tumor cell count (CTC) was generally low, even in advanced stages of the disease. Additionally, the gene expression analysis showed upregulation of cancer markers CD133, KRT19, and MUC1 in half of the tested samples, with some samples showing upregulation of multiple cancer markers. These findings suggest that Filipino patients with lung adenocarcinoma have a diverse molecular profile and confirm the presence of reported EGFR and ALK mutations. The study highlights the potential diagnostic and therapeutic utility of the identified cancer markers and emphasizes the importance of molecular profiling in selecting appropriate lung cancer therapy and monitoring treatment response. This information is valuable for improving patient outcomes and managing patient survival.

Asset Subtitle

Francisco Heralde

Meta Tag

Speaker Francisco Heralde

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

clinical study

molecular profile

Filipino patients

lung adenocarcinoma

cancer death

EGFR mutations

ALK mutation

circulating tumor cell count

gene expression analysis

cancer markers